Cited by 421Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical MethodsHemoglobin structure and function

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Open access

Egrie, Joan C, Dwyer, Erik, Browne, Jeffrey K, Hitz, Anna, Lykos, Michele A·2003·Experimental Hematology

Open this paper in CoChat — free account Open PDF

Abstract

Objective Experiments on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of EPO, its circulating half-life, and in vivo bioactivity. This led to the hypothesis that an EPO analogue engineered to contain additional oligosaccharide chains would have enhanced biological activity. Darbepoetin alfa, a hyperglycosylated recombinant human EPO (rHuEPO) analogue with two extra carbohydrate chains, was designed and developed to test this hypothesis. Materials and methods Comparative pharmacokinetic and pharmacodynamic studies and biochemical analyses of darbepoetin alfa and rHuEPO were performed to define the consequences of the increased carbohydrate content. Results Due to its increased sialic acid-containing carbohydrate content, darbepoetin alfa has a higher molecular weight, a greater negative charge, and a approximately fourfold lower EPO receptor binding activity than rHuEPO. It also has a threefold longer circulating half-life than rHuEPO in rats and dogs. In spite of its lower receptor binding, and perhaps counterintuitively, darbepoetin alfa is significantly more potent in vivo than rHuEPO. Due to the pharmacokinetic differences, the relative potency of the two molecules varies as a function of the dosing frequency. Darbepoetin alfa is 3.6-fold more potent than rHuEPO in increasing the hematocrit of normal mice when each is administered thrice weekly, but when the administration frequency is reduced to once weekly, darbepoetin alfa is approximately 13-fold to 14-fold more potent than rHuEPO. Conclusions Increasing the sialic acid-containing carbohydrate content beyond the maximum found in EPO leads to a molecule with a longer circulating half-life and thereby an increased in vivo potency that can be administered less frequently.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0301-472x(03)00006-7

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY
Greenwood, F. C., Hunter, W., & GLOVER, J. S. (1963) · Biochemical Journal · doi:10.1042/bj0890114 · Cited by 10,141
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA · doi:10.1001/jama.1996.03540120077042 · Cited by 2,375
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 1,987
Self-citation
EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSIS
Winearls, C., Pippard, M. J., Downing, M. R., Oliver, D., Reid, C. D. L., & Cotes, P. M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92192-6 · Cited by 1,401
Applied Biopharmaceutics and Pharmacokinetics.
(1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-6-826_2 · Cited by 1,209
Erythropoietin
Krantz, S. B. (1991) · Blood · doi:10.1182/blood.v77.3.419.419 · Cited by 881
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citation
Expression cloning of the murine erythropoietin receptor
D’Andrea, A. D., Lodish, H. F., & Wong, G. G. (1989) · Cell · doi:10.1016/0092-8674(89)90965-3 · Cited by 737

Show all 47 references

Research works printed but not linked: 1

Sowade, 1998, The safety of treatment with recombinant human erythropoietin in clinical use, Int J Mol Med., 1, 303

Sorted by citations

Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Glycoprotein Synthesis: An Update
Gamblin, D. P., Scanlan, E. M., & Davis, B. G. (2008) · Chemical Reviews · doi:10.1021/cr078291i · Cited by 593
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Schiestl, M., Stangler, T., Torella, C., ČEPELJNIK, T., Toll, H., & Grau, R. (2011) · Nature Biotechnology · doi:10.1038/nbt.1839 · Cited by 484
Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals
Butler, M. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1980-8 · Cited by 493
Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins
Sinclair, A. M., & Elliott, S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20319 · Cited by 461
Glycosylation of Therapeutic Proteins
Solá, R. J., & Griebenow, K. H. (2010) · BioDrugs · doi:10.2165/11530550-000000000-00000 · Cited by 443
Quantifying Western blots: Pitfalls of densitometry
Gassmann, M., Grenacher, B., Rohde, B., & Vogel, J. (2009) · ELECTROPHORESIS · doi:10.1002/elps.200800720 · Cited by 365
Erythropoietins: A common mechanism of action
Elliott, S., Pham, E., & Macdougall, I. C. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.08.003 · Cited by 246
Therapeutic Potential of Erythropoietin and its Structural or Functional Variants in the Nervous System
Sirén, A., Faßhauer, T., Bartels, C., & Ehrenreich, H. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.041 · Cited by 223
Glycomics: a pathway to a class of new and improved therapeutics
Shriver, Z. H., Raguram, S., & Sasisekharan, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1521 · Cited by 221
Control of rHuEPO biological activity: The role of carbohydrate
Elliott, S., Egrie, J. C., Browne, J., Lorenzini, T., Busse, L. A., Rogers, N. E., & Ponting, I. L. O. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.08.004 · Cited by 198
Self-citation
NASPGHAN Practice Guidelines
Mack, C. L., González‐Peralta, R. P., Gupta, N. A., Leung, D. H., Narkewicz, M. R., Roberts, E. A., Rosenthal, P. J., & Schwarz, K. B. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318258328d · Cited by 193
Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease
Zhu, Y., Jiang, J.-L., Gumlaw, N., Zhang, J., Bercury, S. D., Ziegler, R. J., Lee, K. S., Kudo, M., Canfield, W. M., Edmunds, T., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.37 · Cited by 180
Engineering of Therapeutic Proteins Production in Escherichia coli
Kamionka, M. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111794295693 · Cited by 179
Optimisation of the Cellular Metabolism of Glycosylation for Recombinant Proteins Produced by Mammalian Cell Systems
Butler, M. (2005) · Cytotechnology · doi:10.1007/s10616-005-4537-x · Cited by 178
Production of therapeutic antibodies with controlled fucosylation
Yamane‐Ohnuki, N., & Satoh, M. (2009) · mAbs · doi:10.4161/mabs.1.3.8328 · Cited by 173
Exploring and Exploiting the Therapeutic Potential of Glycoconjugates
Doores, K. J., Gamblin, D. P., & Davis, B. G. (2005) · Chemistry - A European Journal · doi:10.1002/chem.200500557 · Cited by 164
Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells
Byrne, B. J., Donohoe, G. G., & O’Kennedy, R. J. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.02.010 · Cited by 151
Passage of erythropoietic agents across the blood–brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa
Banks, W. A., Jumbe, N. L. ‘., Farrell, C. L., Niehoff, M. L., & Heatherington, A. C. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.035 · Cited by 145
Inhaled proteins: Challenges and perspectives
Depreter, F., Pilcer, G., & Amighi, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.031 · Cited by 145
N-Glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans
Castilho, A., Gattinger, P., Grass, J., Jeż, J., Pabst, M., Altmann, F., Gorfer, M., Strasser, R., & Steinkellner, H. (2011) · Glycobiology · doi:10.1093/glycob/cwr009 · Cited by 135
Overproduction of recombinant proteins in plants
Egelkrout, E. M., Rajan, V., & Howard, J. A. (2011) · Plant Science · doi:10.1016/j.plantsci.2011.12.005 · Cited by 132
Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
Aapro, M., JELKMANN, W. E. B., Constantinescu, S. N., & Leyland-Jones, B. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.42 · Cited by 122
Neuroprotective Effect of Darbepoetin Alfa, a Novel Recombinant Erythropoietic Protein, in Focal Cerebral Ischemia in Rats
Belayev, L., Khoutorova, L., Zhao, W., Vigdorchik, A. V., Belayev, A., Busto, R., Magal, E., & Ginsberg, M. D. (2005) · Stroke · doi:10.1161/01.str.0000160753.36093.da · Cited by 118
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia
Fan, Q., Leuther, K. K., Holmes, C. P., Fong, K. L., Zhang, J., Velkovska, S., Chen, M., Mortensen, R. B., Leu, K., Green, J. M., et al. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.05.012 · Cited by 114
Glycosylation of therapeutic proteins in different production systems
Werner, R. G., Kopp, K., & Schlueter, M. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00199.x · Cited by 113
Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides
Datta‐Mannan, A. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086488 · Cited by 113
Cancer-related anemia and recombinant human erythropoietin—an updated overview
Bohlius, J., Weingart, O., Trelle, S., & Engert, A. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0451 · Cited by 110
Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited
Wang, W., & Prueksaritanont, T. (2010) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.708 · Cited by 104
A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer
Schwartzberg, L. S., Yee, L., Senecal, F. M., Charu, V., Tomita, D. K., Wallace, J. F., & Rossi, G. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-696 · Cited by 104
Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia
Canon, J.-L. R., Vansteenkiste, J., Bodoky, G., Mateos, M., Bastit, L., Ferreira, I., Rossi, G., & Amado, R. G. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj053 · Cited by 103
High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
Mannone, L., Gardin, C., Quarré, M. C., Bernard, J. F., Vassilieff, D., Adès, L., Park, S., Vaultier, S., Hamza, F., Beyne‐rauzy, M. O., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06070.x · Cited by 100
Interspecies Scaling and Prediction of Human Clearance: Comparison of Small- and Macro-Molecule Drugs
Huh, Y., Smith, D. E., & Rose Feng, M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.598582 · Cited by 98
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 100
Engineering of Sialylated Mucin-type O-Glycosylation in Plants
Castilho, A., Neumann, L., Daskalova, S. M., Mason, H. S., Steinkellner, H., Altmann, F., & Strasser, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.402685 · Cited by 96
Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
Stasi, R., Abruzzese, E., Lanzetta, G., Terzoli, E., & Amadori, S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi400 · Cited by 96
Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromes
Musto, P., Lanza, F., Balleari, E., Grossi, A., Falcone, A. P., Sanpaolo, G., Bodenizza, C., Scalzulli, P. R., Sala, A. L., Campioni, D., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05288.x · Cited by 95
Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells
Prunier, F., Pfister, O., Hadri, L., Liang, L., del Monte, F., Liao, R., & Hajjar, R. J. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00357.2006 · Cited by 94
Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa
Glaspy, J. A., Henry, D. H., Patel, R., Tchekmedyian, S., Applebaum, S., Berdeaux, D. H., Lloyd, R., Berg, R., Austin, M., & Rossi, G. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.01.021 · Cited by 90
Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy
Ranjan, A. K., & Gulati, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206653 · Cited by 117
Modifications of therapeutic proteins: challenges and prospects
Jenkins, N. (2007) · Cytotechnology · doi:10.1007/s10616-007-9075-2 · Cited by 86
Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects
Salamin, O., Kuuranne, T., Saugy, M., & Leuenberger, N. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.033 · Cited by 84
Post-translational structural modifications of immunoglobulin G and their effect on biological activity
Hmiel, L. K., Brorson, K., & Boyne, M. T. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8108-x · Cited by 87
Glycoinsulins: Dendritic Sialyloligosaccharide-Displaying Insulins Showing a Prolonged Blood-Sugar-Lowering Activity
Sato, M., Furuike, T., Sadamoto, R., Fujitani, N., Nakahara, T., Niikura, K., Monde, K., Kondo, H., & Nishimura, S. (2004) · Journal of the American Chemical Society · doi:10.1021/ja046426l · Cited by 78
QUANTITY: An Isobaric Tag for Quantitative Glycomics
Yang, S., Wang, M., Chen, L., Yin, B., Guo-qiang, S., Turko, I. V., Phinney, K. W., Betenbaugh, M. J., Zhang, H., & Li, S. (2015) · Scientific Reports · doi:10.1038/srep17585 · Cited by 72
The human Cas1 protein: A sialic acid-specific O-acetyltransferase?
Arming, S., Wipfler, D., Mayr, J., Merling, A., Vilas, U., Schauer, R., Schwartz‐Albiez, R., & Vlasak, R. (2010) · Glycobiology · doi:10.1093/glycob/cwq153 · Cited by 67
Glycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Erythropoietin Produced in a Human Cell Line (Dynepo) Has Significant Differences in Glycosylation Compared with Erythropoietins Produced in CHO Cell Lines
Shahrokh, Z., Royle, L., Saldova, R., Bones, J., Abrahams, J. L., Artemenko, N. V., Flatman, S., Davies, M., Baycroft, A., Sehgal, S., et al. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100353a · Cited by 69
Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease
Warady, B. A., Arar, M. Y., Lerner, G. R., Nakanishi, A. M., & Stehman‐Breen, C. O. (2006) · Pediatric Nephrology · doi:10.1007/s00467-006-0071-0 · Cited by 68
Glycosylation of the enhanced aromatic sequon is similarly stabilizing in three distinct reverse turn contexts
Price, J. L., Powers, D. L., Powers, E. T., & Kelly, J. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105880108 · Cited by 68
The Significance of Glycosylation Analysis in Development of Biopharmaceuticals
Kawasaki, N., Itoh, S., Hashii, N., Takakura, D., Qin, Y., Huang, X., & Yamaguchi, T. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.796 · Cited by 67
The Use of Darbepoetin to Stimulate Erythropoiesis in Anemia of Chronic Kidney Disease in Cats: 25 Cases
Chalhoub, S., Langston, C. E., & Farrelly, J. (2012) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2011.00864.x · Cited by 73
N‐glycosylation of enhanced aromatic sequons to increase glycoprotein stability
Price, J. L., Culyba, E. K., Chen, W., Murray, A. N., Hanson, S. R., Wong, C., Powers, E. T., & Kelly, J. W. (2012) · Biopolymers · doi:10.1002/bip.22030 · Cited by 67
Strategies for Glycoengineering Therapeutic Proteins
Dammen‐Brower, K., Epler, P., Zhu, S. E., Bernstein, Z. J., Stabach, P. R., Braddock, D. T., Spangler, J. B., & Yarema, K. J. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.863118 · Cited by 70
Glycosylation Shapes the Efficacy and Safety of Diverse Protein, Gene and Cell Therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Anemia of Renal Disease
Chalhoub, S., Langston, C. E., & Eatroff, A. E. (2011) · Journal of Feline Medicine and Surgery · doi:10.1016/j.jfms.2011.07.016 · Cited by 83
Erythropoietin elevates but not voluntary wheel running in mice
Kolb, E. M., Kelly, S. A., Middleton, K. M., Sermsakdi, L. S., Chappell, M. A., & Garland, T. (2010) · Journal of Experimental Biology · doi:10.1242/jeb.029074 · Cited by 64
Darbepoetin Alfa Effectively Treats Anemia in Patients with Chronic Kidney Disease with de novo Every-Other-Week Administration
Toto, R. D., Pichette, V., Navarro, J., Brenner, R., Carroll, W., Liu, W., & Roger, S. D. (2004) · American Journal of Nephrology · doi:10.1159/000080452 · Cited by 64
Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey
Repetto, L. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.03.004 · Cited by 63
Glycosylation of monoclonal antibody products: Current status and future prospects
Batra, J., & Rathore, A. S. (2016) · Biotechnology Progress · doi:10.1002/btpr.2366 · Cited by 68
Formulating erythropoietin-loaded sustained-release PLGA microspheres without protein aggregation
GENG, Y., Yuan, W., WU, F., CHEN, J., He, M., & Jin, T. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.06.011 · Cited by 62
Total Chemical Synthesis of a Nonfibrillating Human Glycoinsulin
Hossain, M. A., Okamoto, R., Karas, J. A., Praveen, P., Liu, M., Forbes, B. E., Wade, J. D., & Kajihara, Y. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11424 · Cited by 62
N-Glycosylation Increases the Circulatory Half-Life of Human Growth Hormone
Flintegaard, T. V., Thygesen, P., Rahbek-Nielsen, H., Levery, S. B., Kristensen, C., Clausen, H., & Bolt, G. R. (2010) · Endocrinology · doi:10.1210/en.2010-0574 · Cited by 61
Longer action means better drug: Tuning up protein therapeutics
Szlachcic, A., Zakrzewska, M., & Otlewski, J. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.03.005 · Cited by 61
Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact
Kiss, Z., Elliott, S. G., Jedynasty, K., Tesař, V., & Szegedi, J. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0780-y · Cited by 61
Structural Requirements for Additional N-Linked Carbohydrate on Recombinant Human Erythropoietin
Elliott, S., Chang, D., Delorme, E., Eris, T., & Lorenzini, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311095200 · Cited by 61
Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: Disease Progression and Survival Analysis From Four Randomized, Double-Blind, Placebo-Controlled Trials
Hedenus, M., Vansteenkiste, J., Kotasek, D., Austin, M., & Amado, R. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.434 · Cited by 61
ERYTHROPOIETIN PROMOTES THE RECOVERY OF ERECTILE FUNCTION FOLLOWING CAVERNOUS NERVE INJURY
Allaf, M. E., Höke, A., & Burnett, A. L. “. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000176808.94610.dd · Cited by 60
Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Tan, H., Su, W., Zhang, W., Wang, P., Sattler, M., & Zou, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206105232 · Cited by 62
Membrane glycomics reveal heterogeneity and quantitative distribution of cell surface sialylation
Park, D., Xu, G., Wong, M., Phoomak, C., Liu, M., Haigh, N. E., Wongkham, S., Yang, P., Maverakis, E., & Lebrilla, C. B. (2018) · Chemical Science · doi:10.1039/c8sc01875h · Cited by 60
Single-Dose Darbepoetin Administration to Anemic Preterm Neonates
Warwood, T. L., Ohls, R. K., Wiedmeier, S. E., Lambert, D. K., Jones, C., Scoffield, S. H., Gupta, N., Veng‐Pedersen, P., & Christensen, R. D. (2005) · Journal of Perinatology · doi:10.1038/sj.jp.7211387 · Cited by 57
The Use of Growth Factors to Manage the Hematologic Side Effects of PEG-Interferon Alfa and Ribavirin
Collantes, R. S., & Younossi, Z. M. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000142583.00102.45 · Cited by 57
Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q
Nimer, S. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6715 · Cited by 56
Anemia of Chronic Disease (Anemia of Inflammation)
Agarwal, N., & Prchal, J. T. (2009) · Acta Haematologica · doi:10.1159/000243794 · Cited by 56
Effectiveness of Darbepoetin Alfa Versus Epoetin Alfa in Patients with Chemotherapy-Induced Anemia Treated in Clinical Practice
Patton, J. F., Reeves, T., & Wallace, J. F. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-451 · Cited by 54
Protein Engineering for Cardiovascular Therapeutics
Jay, S. M., & Lee, R. T. (2013) · Circulation Research · doi:10.1161/circresaha.113.300215 · Cited by 51
Capillary electrophoresis for the analysis of glycoprotein pharmaceuticals
Kamoda, S., & Kakehi, K. (2006) · Electrophoresis · doi:10.1002/elps.200500853 · Cited by 52
Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy
Agoram, B. M., Heatherington, A. C., & Gastonguay, M. R. (2006) · The AAPS Journal · doi:10.1208/aapsj080364 · Cited by 52
Protein Glycosylation and Its Impact on Biotechnology
Berger, M., Kaup, M., & Blanchard, V. (2011) · Springer eBooks · doi:10.1007/10_2011_101 · Cited by 51
Integrating cell-level kinetic modeling into the design of engineered protein therapeutics
Rao, B. M., Lauffenburger, D. A., & Wittrup, K. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1064 · Cited by 50
Analysis of intact erythropoietin and novel erythropoiesis‐stimulating protein by capillary electrophoresis‐electrospray‐ion trap mass spectrometry
Giménez, E., Benavente, F., Barbosa, J., & Sanz‐Nebot, V. (2008) · Electrophoresis · doi:10.1002/elps.200700788 · Cited by 49
Darbepoetin Alfa Protects the Rat Heart Against Infarction: Dose-Response, Phase of Action, and Mechanisms
Baker, J. E., Kozik, D. J., Hsu, A. K., Fu, X., Tweddell, J. S., & Gross, G. J. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318040cf81 · Cited by 49
Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study
Κoutroubakis, I. E., Κarmiris, K., Makreas, S., Xidakis, C., Niniraki, M., & Kouroumalis, E. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200604000-00017 · Cited by 49
Once-Monthly Administration of Darbepoetin Alfa for the Treatment of Patients with Chronic Heart Failure and Anemia
Cleland, J. G. F., Sullivan, J. T., Ball, S., Horowitz, J. D., Agoram, B. M., Rosser, D., Yates, W., Tin, L., Fuentealba, P., & Burton, P. B. J. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000167013.77092.c4 · Cited by 49
The emerging role of cellular post-translational modifications in modulating growth and productivity of recombinant Chinese hamster ovary cells
Bryan, L. L. K., CLYNES, M. M., & Meleady, P. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107757 · Cited by 50
NEUROPROTECTIVE EFFECT OF ERYTHROPOIETIN AND DARBEPOETIN ALFA AFTER EXPERIMENTAL INTRACEREBRAL HEMORRHAGE
Grasso, G., Graziano, F., Sfacteria, A., Carletti, F., Meli, F., Maugeri, R., Passalacqua, M., Certo, F., Fazio, M., Buemi, M., et al. (2009) · Neurosurgery · doi:10.1227/01.neu.0000347475.73347.5f · Cited by 47
Pharmacology of darbepoetin alfa
Macdougall, I. C., Padhi, D., & Jang, G. R. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm160 · Cited by 47
Prototype Amperometric Biosensor for Sialic Acid Determination
Marzouk, S. A. M., Ashraf, S. M., & Tayyari, K. A. A. (2006) · Analytical Chemistry · doi:10.1021/ac061886d · Cited by 47
Supplementing glycosylation: A review of applying nucleotide-sugar precursors to growth medium to affect therapeutic recombinant protein glycoform distributions
Blondeel, E. J. M., & Aucoin, M. G. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.06.008 · Cited by 46
Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content
Chia, S., Tay, S. J., Song, Z., Yang, Y., Walsh, I., & Pang, K. T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114757 · Cited by 46
Cardiovascular Effects of Erythropoietin
Santhanam, A. V. R., d’Uscio, L. V., & Katušić, Z. S. (2010) · Advances in pharmacology · doi:10.1016/b978-0-12-385061-4.00009-x · Cited by 44
Recent developments in doping testing for erythropoietin
Reichel, C. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-5116-y · Cited by 44
Erythropoietin as a Novel Brain and Kidney Protective Agent
Moore, E., Bellomo, R., & Nichol, A. D. (2011) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1103900306 · Cited by 43
Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development
Agoram, B. M., & Demin, O. O. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.001 · Cited by 43
A potent erythropoietin-mimicking human antibody interacts through a novel binding site
Liu, Z., Stoll, V. S., DeVries, P. J., Jakob, C. G., Xie, N., Simmer, R. L., Lacy, S. E., Egan, D. A., Harlan, J. E., Lesniewski, R. R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083998 · Cited by 43
CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools
Sathyanarayana, P., Houde, E., Marshall, D. C., Volk, A. L., Makropoulos, D., Emerson, C., Pradeep, A., Bugelski, P. J., & Wojchowski, D. M. (2009) · Blood · doi:10.1182/blood-2008-08-172320 · Cited by 43
Galactosyltransferase 4 is a major control point for glycan branching in N-linked glycosylation
McDonald, A. G., Hayes, J. M., Bezak, T., Gluchowska, S. A., Cosgrave, E. F. J., Struwe, W. B., Stroop, C. J. M., Kok, H. J., van de Laar, T., Rudd, P. M., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.151878 · Cited by 44
Production and characterization of long-acting recombinant human albumin–EPO fusion protein expressed in CHO cell
Joung, C.-H., Shin, J.-Y., Koo, J.-K., Lim, J. J., Wang, J.-S., Lee, S.-J., Tan, H.-K., Kim, S.-L., & Lim, S. (2009) · Protein Expression and Purification · doi:10.1016/j.pep.2009.07.003 · Cited by 43
Emerging Role of Anemia in Heart Failure
Mitchell, J. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.12.015 · Cited by 43
Glycosylation of Therapeutic Proteins: A Critical Quality Attribute
Delobel, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1241-5_1 · Cited by 42

Authors: Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A.
Affiliations: Amgen (United States) (US)
Corresponding author: Egrie, Joan C
Venue: Experimental Hematology
Publisher: Elsevier BV
Published: 2003-04
Volume: 31
Issue: 4
Pages: 290-299
ISSN: 0301-472X (ISSN-L)
DOI: 10.1016/s0301-472x(03)00006-7
OpenAlex: W2169177790
Cited by: 421
References: 47
Citations by year: 2026: 10 · 2025: 14 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 12 · 2020: 3 · 2019: 12 · 2018: 14 · 2017: 12 · 2016: 13 · 2015: 19 · 2014: 16 · 2013: 16 · 2012: 19
FWCI: 16.09
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 7008 d)
Locations: Experimental Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
Keywords: darbepoetin alfa, recombinant human erythropoietin, erythropoietin analogues, hyperglycosylation, serum half-life, in vivo potency, hematocrit, dosing frequency, pharmacokinetics, pharmacodynamics
MeSH terms: Darbepoetin alfa, Animals, Carbohydrates, Dogs, Dose-Response Relationship, Drug, Electrochemistry, Electrophoresis, Polyacrylamide Gel, Erythropoietin, Half-Life, Hematocrit, Humans, Kinetics, Male, Molecular Weight, Recombinant Proteins, Rats, Sprague-Dawley, Receptors, Erythropoietin, N-Acetylneuraminic Acid, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks